Arimidex
Arimidex
Anastrozole — potent aromatase inhibitor for estrogen control. Essential on-cycle support for preventing estrogenic side effects.
Save 10% when you pay in crypto (BTC · ETH · USDT)
Free shipping on orders over $250
Research use only. Products are not intended for human consumption.
We accept
Interac e-Transfer · BTC · ETH · USDT crypto −10%
How ordering works
- 01Place your order — no payment is taken on this site.
- 02Payment instructions arrive by email reply (Interac e-Transfer or crypto).
- 03Paid before 4 PM EST → same-day dispatch with tracking number.
Refrigerated SKU? Ships in an insulated cold-pack mailer. You receive a packaging photograph within 4 hours of dispatch.
- Janoshik verified — per-batch third-party purity testing
- Discreet — plain packaging, no brand markings
- Cold-pack mailer for refrigerated SKUs
- Refund + retest if a batch fails purity
Complete protocols
Build your stack
Stacks that include Arimidex — protocol components priced together, bulk savings applied automatically.
At a glance
At a glance
- Concentration
- 50 × 1mg
- Purity
- USP-equivalent ≥98%
- Route
- Oral
- Storage
- Room temperature, dry, away from light.
Compound profile
Anastrozole is a potent, selective, non-steroidal aromatase inhibitor (AI) originally developed by AstraZeneca for the treatment of estrogen receptor-positive breast cancer in postmenopausal women. It belongs to the third generation of aromatase inhibitors, which represented a significant advancement over earlier anti-estrogenic agents. Anastrozole works by reversibly binding to the aromatase enzyme (CYP19A1), the enzyme responsible for converting androgens (testosterone, androstenedione) into estrogens (estradiol, estrone).
Anastrozole is a potent, selective, non-steroidal aromatase inhibitor (AI) originally developed by AstraZeneca for the treatment of estrogen receptor-positive breast cancer in postmenopausal women. It belongs to the third generation of aromatase inhibitors, which represented a significant advancement over earlier anti-estrogenic agents. Anastrozole works by reversibly binding to the aromatase enzyme (CYP19A1), the enzyme responsible for converting androgens (testosterone, androstenedione) into estrogens (estradiol, estrone).
The mechanism is competitive inhibition: Anastrozole occupies the active site of the aromatase enzyme, preventing substrate binding without permanently altering the enzyme's structure. This is a critical distinction from "suicidal" inhibitors like Exemestane — when Anastrozole is discontinued, aromatase activity resumes as the compound clears. Clinical data shows that Anastrozole suppresses serum estradiol by approximately 80–85% at the standard 1 mg daily dose. This level of suppression is usually more than sufficient for managing estrogen-related side effects in anabolic research protocols.
In the context of anabolic steroid research, Arimidex is the most widely used AI for controlling estrogenic side effects that arise from aromatizing compounds (Testosterone, Dianabol, Equipoise, Deca Durabolin, and others). These effects include subcutaneous water retention, elevated blood pressure secondary to fluid retention, and gynecomastia (development of glandular breast tissue). By titrating estrogen downward, Arimidex allows researchers to retain the anabolic benefits of aromatizing compounds while minimizing their estrogenic liabilities.
Arimidex is essential for any researcher running aromatizing compounds, from first cycle onward. It is a "have on hand" compound even for researchers who believe they may not need it — gynecomastia onset can be rapid once it begins. Researchers typically start at the lowest effective dose and titrate upward based on bloodwork, as over-suppression of estrogen carries its own consequences: joint pain, mood disturbance, impaired lipid profiles, and reduced IGF-1 signaling. Maintaining estradiol within the 20–30 pg/mL range is the standard target.
Anastrozole has a half-life of approximately 46–50 hours, meaning every-other-day (EOD) dosing is effective for most protocols. Standard research dosages range from 0.25 mg EOD to 1 mg EOD, with dosing frequency and amount calibrated to the degree of aromatization from the compound stack being used. Anastrozole does not carry hepatotoxicity in the traditional sense, and administration can continue for the duration of the aromatizing cycle without liver-support concerns. Bloodwork (sensitive estradiol assay, E2) is the gold standard for dose calibration — subjective symptom assessment alone is unreliable.
How to use
Injection technique, site rotation, and frequency guidance. Typical protocols split the weekly dose into 2 injections.
Dose ranges published in the peptide-research literature vary considerably. Research protocols should be designed by a qualified researcher and use the lowest effective dose consistent with the hypothesis being tested. Half-life determines dosing frequency — shorter half-lives usually require daily dosing, while long-acting analogues tolerate weekly administration.
For compound-specific dose theory, see the half-life dosing math guide and the stacking theory reference.
Independent lab verification
Research disclaimer
For research and laboratory use only. Not for human or veterinary consumption. Nova Pharma sells to qualified researchers of legal age and ships to Canadian addresses only. See disclaimer and terms.
At a glance
At a glance
- Concentration
- 50 × 1mg
- Purity
- USP-equivalent ≥98%
- Route
- Oral
- Storage
- Room temperature, dry, away from light.
Compound profile
Anastrozole is a potent, selective, non-steroidal aromatase inhibitor (AI) originally developed by AstraZeneca for the treatment of estrogen receptor-positive breast cancer in postmenopausal women. It belongs to the third generation of aromatase inhibitors, which represented a significant advancement over earlier anti-estrogenic agents. Anastrozole works by reversibly binding to the aromatase enzyme (CYP19A1), the enzyme responsible for converting androgens (testosterone, androstenedione) into estrogens (estradiol, estrone).
Anastrozole is a potent, selective, non-steroidal aromatase inhibitor (AI) originally developed by AstraZeneca for the treatment of estrogen receptor-positive breast cancer in postmenopausal women. It belongs to the third generation of aromatase inhibitors, which represented a significant advancement over earlier anti-estrogenic agents. Anastrozole works by reversibly binding to the aromatase enzyme (CYP19A1), the enzyme responsible for converting androgens (testosterone, androstenedione) into estrogens (estradiol, estrone).
The mechanism is competitive inhibition: Anastrozole occupies the active site of the aromatase enzyme, preventing substrate binding without permanently altering the enzyme's structure. This is a critical distinction from "suicidal" inhibitors like Exemestane — when Anastrozole is discontinued, aromatase activity resumes as the compound clears. Clinical data shows that Anastrozole suppresses serum estradiol by approximately 80–85% at the standard 1 mg daily dose. This level of suppression is usually more than sufficient for managing estrogen-related side effects in anabolic research protocols.
In the context of anabolic steroid research, Arimidex is the most widely used AI for controlling estrogenic side effects that arise from aromatizing compounds (Testosterone, Dianabol, Equipoise, Deca Durabolin, and others). These effects include subcutaneous water retention, elevated blood pressure secondary to fluid retention, and gynecomastia (development of glandular breast tissue). By titrating estrogen downward, Arimidex allows researchers to retain the anabolic benefits of aromatizing compounds while minimizing their estrogenic liabilities.
Arimidex is essential for any researcher running aromatizing compounds, from first cycle onward. It is a "have on hand" compound even for researchers who believe they may not need it — gynecomastia onset can be rapid once it begins. Researchers typically start at the lowest effective dose and titrate upward based on bloodwork, as over-suppression of estrogen carries its own consequences: joint pain, mood disturbance, impaired lipid profiles, and reduced IGF-1 signaling. Maintaining estradiol within the 20–30 pg/mL range is the standard target.
Anastrozole has a half-life of approximately 46–50 hours, meaning every-other-day (EOD) dosing is effective for most protocols. Standard research dosages range from 0.25 mg EOD to 1 mg EOD, with dosing frequency and amount calibrated to the degree of aromatization from the compound stack being used. Anastrozole does not carry hepatotoxicity in the traditional sense, and administration can continue for the duration of the aromatizing cycle without liver-support concerns. Bloodwork (sensitive estradiol assay, E2) is the gold standard for dose calibration — subjective symptom assessment alone is unreliable.
How to use
Injection technique, site rotation, and frequency guidance. Typical protocols split the weekly dose into 2 injections.
Dose ranges published in the peptide-research literature vary considerably. Research protocols should be designed by a qualified researcher and use the lowest effective dose consistent with the hypothesis being tested. Half-life determines dosing frequency — shorter half-lives usually require daily dosing, while long-acting analogues tolerate weekly administration.
For compound-specific dose theory, see the half-life dosing math guide and the stacking theory reference.
Independent lab verification
Research disclaimer
For research and laboratory use only. Not for human or veterinary consumption. Nova Pharma sells to qualified researchers of legal age and ships to Canadian addresses only. See disclaimer and terms.
Read the research
Reference articles from the lab covering this compound.
beginner guides
Your First Steroid Cycle: Why Testosterone-Only Is the Only Right Answer
Why your first steroid cycle must be testosterone-only. Detailed protocol, week-by-week guide, expected results, and why adding Dbol or Anavar to your first cycle is a mistake you'll regret.
beginner guides
Dianabol Beginner Cycle: What to Expect Week by Week (With PCT)
Complete Dianabol beginner cycle guide with week-by-week results timeline, 30mg dosing protocol, estrogen management, liver support, PCT with Nolvadex, and realistic expectations for Canadian users.
beginner guides
Testosterone Enanthate Beginner Cycle: The Complete 12-Week Protocol
The complete testosterone enanthate beginner cycle guide. 12-week protocol with dosing, injection schedule, AI management, PCT, bloodwork timing, week-by-week results, and common mistakes to avoid.
